Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ATNM |
---|---|---|
09:32 ET | 6762 | 8 |
09:34 ET | 575 | 7.98 |
09:36 ET | 869 | 8.0499 |
09:38 ET | 1900 | 7.94 |
09:39 ET | 113 | 7.95 |
09:41 ET | 300 | 8 |
09:45 ET | 2222 | 8.01 |
09:48 ET | 1168 | 8.05 |
09:50 ET | 300 | 8.04 |
09:52 ET | 555 | 8.04 |
09:54 ET | 400 | 8.015 |
09:57 ET | 100 | 7.99 |
09:59 ET | 450 | 7.99 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Actinium Pharmaceuticals Inc | 236.2M | -4.6x | --- |
Zura Bio Ltd | 237.5M | -2.2x | --- |
Renovaro Inc | 234.5M | -2.0x | --- |
Omeros Corp | 234.1M | -1.4x | --- |
Inovio Pharmaceuticals Inc | 231.6M | -1.6x | --- |
Shattuck Labs Inc | 236.8M | -2.5x | --- |
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $236.2M |
---|---|
Revenue (TTM) | $81.0K |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.21 |
EPS | $-1.72 |
Book Value | $1.32 |
P/E Ratio | -4.6x |
Price/Sales (TTM) | 2,915.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -61,645.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.